3 results
Primary:to evaluate the effects of a moderate CYP3A4/5 inhibitor, diltiazem on the pharmacokinetics and pharmacodynamics (Thrombin and TRAP-induced platelet aggregation) of the study drug and its known metabolitessecundary:to evaluate the effects of…
The sponsor is developing a biological product (DRL_AB) similar to the approved medicine Orencia®. As part of medical-scientific studies to confirm the similarity of the biological products, the Sponsor wants to compare DRL_AB with EU-approved…
Objectives: The primary objective of this study is to evaluate the effect of response to treatment (assessed by SVR12 status) on the long-term progression of liver disease in adults with chronic HCV GT1 infection who received treatment with ABT-450/…